Epitopea is a transatlantic cancer immunotherapeutics company.
Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. Cryptigen™ TSAs are discovered by a proprietary approach deploying immunopetidomics, mass spectrometry, genomics, and bioinformatics, which allows the identification of conserved, aberrantly-expressed, tumour-specific antigens, hidden in cancer's 'junk' DNA. These hidden Cryptigen™ TSAs have been identified by research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 25, 2022 | Seed | £10.30M | 6 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Cambridge Innovation Capital | — | Seed |
Harrington Discovery Institute at University Hospitals | — | Seed |
Advent Life Sciences | — | Seed |
CTI Life Sciences Fund | — | Seed |
Fonds de solidarité FTQ | — | Seed |
Novateur Ventures | — | Seed |